Ruzasvir is under clinical development by Atea Pharmaceuticals and currently in Phase II for Hepatitis C. According to GlobalData, Phase II drugs for Hepatitis C have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ruzasvir’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ruzasvir overview
Ruzasvir is under development for the treatment of hepatitis C infection. The drug candidate is administered orally and targets NS5A antigen.
See Also:
Atea Pharmaceuticals overview
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company. It develops, discovers and commercializes therapies for treatment of life-threatening viral infections. The company product pipeline includes bemnifosbuvir (AT-527) for the treatment of COVID-19, the disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and bemnifosbuvir in combination with ruzasvir for the treatment of hepatitis C virus (HCV). Atea Pharmaceuticals carries out purine nucleotide prodrug platform to transform treatment of severe viral diseases. It also includes in development of orally-available antiviral agents for serious viral infections. Atea Pharmaceuticals is headquartered in Boston, Massachusetts, the US.
For a complete picture of Ruzasvir’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
